Smart Inhalers Market

Smart Inhalers Market Outlook (2023-2033)

Worldwide revenue from the smart inhalers market stands at US$ 80.5 Mn in 2022, with the global market estimated to expand at a CAGR of 10.2% to reach US$ 235.7 Mn by the end of 2033.

As assessed by Persistence Market Research, dry powder inhaler (dpi) - based smart inhalers will contribute the largest share of 62.1% among the product category in 2023. The smart inhalers market holds 0.7% of the global respiratory inhalers market valued at US$ 11.2 Bn in 2022.

Sales Analysis of Smart Inhalers Market from 2013 to 2022 Vs Market Outlook for 2023 to 2033

The global market recorded a historic CAGR of 9.5% in the last 9 years from 2013 to 2022.

In general, payers, patients, and prescribers view the expense of treating respiratory disorders as a serious concern. Leading respiratory pharmaceutical and digital health companies are currently developing strategic partnerships in order to create new technologies and open the door for innovation in the field of digital healthcare. As a unique method of encouraging adherence, smart inhalers keep track of drug usage based on respiratory diseases. Additionally, smart inhalers have a sizable potential to enhance outcomes and cut down on medical expenses.

It is anticipated that the availability of better clinical outcomes and the increased prevalence of chronic respiratory disorders (CRDs) will support business expansion.

• Asthma is a serious non-communicable disease that affects both adults and children, and the WHO estimates that over 262 million people worldwide suffered from it in 2019. In addition, 3.23 million deaths in the same year were attributed to chronic obstructive pulmonary disease (COPD).

Globally, the COVID-19 epidemic had an impact on every industry's supply chain. A lack of product inventories was seen in several companies, which made clinical testing, regulatory procedures, and post-approval operations more challenging during the pandemic.

The sector is growing as medical professionals switch to linked medical devices to ensure that patients receive the best treatment and advice possible in the post-pandemic period. Due to the increase in demand for cutting-edge digital technology and solutions for respiration and pulmonary care brought on by COVID-19, smart inhalers are becoming more and more common.

How are Manufacturers Aiding Market Growth?

“Increasing Recommendation for Use of Smart Inhalers by Healthcare Professionals”

As more healthcare professionals recommend smart inhalers and their effectiveness in drug delivery and tracking is understood, it is anticipated that their use will increase. The use of smart inhalers is anticipated to increase due to variables such as enhanced clinical outcomes, improved and better results, and the capacity to track and keep track of clinical data.

The demand for smart inhalers is being fuelled by a growing emphasis on the development of smart inhalers and an increase in initiatives by significant market participants for R&D efforts. In addition, many businesses are using digital technologies in their product lines to improve pharmaceutical effectiveness and asthma and COPD management.

For instance,

• In April 2022, Aptar Pharma, a significant player in the market, unveiled HeroTracker Sense, a cutting-edge digital chronic respiratory e-health solution that transforms a conventional metered dose inhaler into a smart inhaler.

According to the most recent study, patients will likely find it simpler to maintain medication adherence and control symptoms if smart inhalers are adopted.

For example,

• A 2020 Cleveland Clinic study found that patients with COPD using smart inhalers made by the Propeller firm had a considerably lower chance of being admitted to the hospital, with a roughly 35% decrease in visits compared to the previous year.

The leading producers of smart inhalers are making investments to expand into new regions and are concentrating on raising consumer knowledge of their products. To increase sales in other regions, they are also implementing organic and inorganic techniques.

• The FDA has approved Teva Pharmaceutical's AirDuo Digihaler, a renowned pharmaceutical company announced in July 2019. The product is an inhaler with sensors that transmits consumption data to a smartphone and can also be shared with a healthcare professional.
• In May 2021, RYAH Medtech Inc. announced a contract allowing its French partner, Delled SAS, exclusive rights to product distribution and software development for the RYAH smart inhaler.

How is the Growth of the Global Market Restrained?

“Patient's Data Security Can Hamper Market Growth”

The global market for smart inhalers is anticipated to grow slowly due to concerns over patient data security.

A vast majority of patients with respiratory ailments goes undetected and, consequently, mistreated since there is a lack of information regarding the symptoms of COPD and asthma. This is a major factor restricting the expansion of the market for smart inhalers globally.

Around 90% of COPD-related deaths occur in low-income nations, and the majority of persons experiencing COPD symptoms are uninformed of their condition. Within the public health system, there is still a lack of massive support for the use of smart inhalers.

This can be related to the restricted reimbursement situation and patients' lack of technological awareness. Additionally, the device's restricted availability presents a challenge that, given the current situation, will negatively affect the market for smart inhalers in general.

Country-wise Insights

Why is the Market Booming in the U.S.?

“Rising Asthma and COPD in the U.S.”

The U.S. is set to account for around 33.8% share of the global market in 2023, and a similar trend is expected over the forecast period.

High rates of asthma and COPD in the United States and Canada are a driver in the market's expansion. Additionally, about 25 million Americans, or 10% of the population of North America, have asthma.

Why is China Emerging as a Prominent Market for Smart inhalers?

“Rising Smart Inhaler Device Acceptance”

China market is projected to progress at a CAGR of 13.4% over the forecast period.

The global market is driven by high levels of knowledge about the usage of digital devices for effective disease management, rising smart inhaler device acceptance, high levels of technological advancement in the healthcare business, and growth in the internet of things (IoT) use in China.

Due to an increase in the number of people suffering from respiratory ailments brought on by an increase in air pollution over the anticipated period, China's growth rate has increased.

Why is India Considered a Lucrative Market for Smart Inhalers?

“Rising Geriatric Population and Healthcare Infrastructure”

India is set to expand at a CAGR of close to 17.5% over the forecast period.

Healthcare spending per person is steadily rising worldwide. Spending on health and wellness has changed significantly because of people's willingness and ability to spend on these things.

The elderly population in India (those 60 and older) is predicted to increase by 41% over the course of a decade, from 138 million in 2021 to 194 million in 2031, according to the National Statistical Office Elderly in India 2021 report.

India is expected to expand at the fastest growth rate during the forecast period due to the rising geriatric population, the prevalence of chronic respiratory diseases (CRD), the growing healthcare infrastructure, and increasing government activities during the forecast period.

Category-wise Insights

Which Smart Inhalers Product is Driving Market Growth?

In 2023, dry powder inhaler (DPI) - based smart inhalers will capture a dominant share of about 62.1%. Based on product, the market is segmented into dry powdered inhalers (DPIs) and metered dose inhalers (MDIs).

Over the projected period, the dry powdered inhalers (DPIs) segment is anticipated to experience the fastest CAGR. DPIs are currently preferred over pressurised MDIs as well as nebulizers as a treatment for respiratory ailments as a result of growing concerns over the environmental impact of inhaler devices that employ chlorofluorocarbons as propellants.

Which Disease Indication Drives the Global Market?

In 2023, with 60.0% share of the global market revenue, the COPD segment will be the most profitable as compared to asthma in terms of disease indication.

The WHO estimates that 3.23 million deaths in 2019 were directly related to COPD. According to the global burden of disease (GBD) data in 2019, the prevalence and incidence of COPD increased in Saudi Arabia between 1990 and 2019. According to estimates, there were 434,560 COPD patients in the nation in 2019.

Due to exposure to second-hand smoke, air pollution, toxic chemicals and fumes, presence of a genetic condition called Alpha-1 deficiency, and a history of childhood respiratory infection, the COPD segment has gained propulsion as a prime segment of concern in terms of disease indication.

Treatment for people with respiratory disorders can benefit from early diagnosis and identification. Breathing is an essential tool for diagnosing the severity of the infection in these patients and preventing misdiagnosis. Therefore, the market's expansion is driven by the rising prevalence of respiratory disorders.

Which Distribution Channel is Most Preferred for Smart Inhalers?

In 2023, the hospital pharmacy segment will hold the highest share with around 46.1% of the global market revenue. The ageing population and increasing CRD incidence both contribute to the industry's expansion. The senior population considers buying medication from hospital pharmacies since they frequently require hospitalisation for a range of chronic respiratory ailments. The market is divided into hospital pharmacies, retail pharmacies, and online pharmacies based on the distribution route.

Retail pharmacies will be the second leading segment as customers favour retail pharmacies more because of their comfort, flexibility, and convenience, and this tendency is increasing the market need for retail pharmacies. Positive industry growth is being influenced by existing pharmacies' rapid modernization and expansion in order to gain market penetration.

Competitive Landscape

To enhance their market position, players in the market are putting more and more emphasis on partnerships, acquisitions, mergers, and expansion.

For instance,

• Adherium Limited formed a partnership with Trudell Medical Limited in August 2022 to provide remote monitoring and respiratory eHealth solutions to patients in the United States. With the aim of lowering readmissions and improving patient outcomes, both businesses will examine COPD patients after they leave the hospital utilising the Trudell U.S. unit Monaghan Health center and its subsidiary Aetonix's TouchAway platform in conjunction with Adherium's Hailie sensors.
• The U.S. FDA 510(k) approved the Hailie Sensor, which contains physiological parameters for monitoring the use of asthma and COPD medicines for sale in the U.S. region, in September 2021, according to an announcement made by Adherium Limited, a major player in the respiratory eHealth remote monitoring market.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the smart inhalers market, which are available in the full report.

Smart Inhalers Industry Report Scope

Key Segments of the Smart Inhalers Industry Research

By Product:

• Dry Powder Inhaler (DPI)- based Smart Inhalers
• Metered Dose Inhaler (MDI)- based Smart Inhalers

By Disease Indication:

• Asthma
• COPD

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

To know more about delivery timeline for this report Contact Sales